In This Article:
Medifast (NYSE:MED) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$115.7m (down 34% from 1Q 2024).
-
Net loss: US$772.0k (down by 109% from US$8.32m profit in 1Q 2024).
-
US$0.071 loss per share (down from US$0.76 profit in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medifast EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 72%.
Looking ahead, revenue is expected to decline by 21% p.a. on average during the next 2 years, while revenues in the Personal Products industry in the US are expected to grow by 3.7%.
Performance of the American Personal Products industry.
The company's shares are up 8.4% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for Medifast that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.